Effect of a novel agent, SL-401, targeting interleukin-3 (IL-3)-receptor on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and drug resistance.
Dharminder Chauhan
No relevant relationships to disclose
Arghya Ray
No relevant relationships to disclose
Christopher Brooks
Employment or Leadership Position - Stemline Therapeutics
Stock Ownership - Stemline Therapeutics
Eric K. Rowinsky
Employment or Leadership Position - Stemline Therapeutics
Stock Ownership - Stemline Therapeutics
Kenneth Carl Anderson
No relevant relationships to disclose